u/paper_trail_paula

This. The special authorization form is published and reading it before applying changes the outcome.

Why the directory has two tiers, since the question comes up whenever somebody new finds it.

Twenty suppliers have enough independent results, over enough separate lots, over enough time, that the log says something. Those get a page, a test table and a link to their own storefront so you can compare their claims with the record.

The rest — nearly two hundred names — get a row, a band and a report count. Not because they are bad, but because two results is an anecdote about a vial. Manufacturing a score out of that would make the whole directory worthless, and the contrast is the point.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards.

Agreed. And the interval, not the point estimate, is what the trial actually established.

Tracking number redacted from the post above. It identifies both ends of a shipment.

Stretched from seven to ten days and then to twelve over about four months. Appetite told me where the limit was before the scale did.

None of this is a taper plan. What dose holds for you is a question for somebody with your history in front of them.

Yes, and the reason the wider-market table has no scores is that a score built on two reports would be a lie with a decimal point.

Careful. "Nobody has tested Risynth Bio" is a statement about this board, not about the supplier. Say the first thing, not the second.

a claim with no batch number is a marketing document

Left up. It names an operation, it carries a date and a lot, and it is written as a report rather than an accusation.

plan the maintenance phase before you need it

Disagreeing with this bit: a two-kilo range is not drift and treating it as a problem creates one.

Stretching the interval, reducing the dose, or both?

Removed pending evidence. Name a supplier here and you bring a document, a date or a service — that is the sidebar rule and it is not negotiable.

On stopping, since it is the question underneath most posts here.

Withdrawal studies in this class show substantial regain after discontinuation, consistently, across compounds. Appetite returns first, typically well before the scale moves. That is a statement about the pharmacology of a chronic condition, not about anybody’s character, and the framing matters because people quit in shame over an entirely predictable result.

If you are going to stop — for cost, for supply, for any reason — the useful preparation is deciding in advance what you will watch for and what your plan is when appetite comes back. Doing that in advance is much easier than doing it in a panic, and it is a conversation to have with someone who knows your history.

a few kilos of drift is not a relapse

Flair set to Vendor. Also a reminder that we take no money from any supplier in the directory.

What maintenance actually looks like, from the people on this board who have been in it longest.

You find a dose or an interval that holds the weight with side effects you barely notice, and then you stop optimising. Weigh monthly rather than daily. Expect a couple of kilos of range and do not act on it. Keep the habits that did the work in the losing phase, because they are the part that has to outlive the dose.

The most common mistake described here is treating arrival as a plateau and pushing the dose to chase a number chosen at week one by a person who did not yet know what maintenance felt like.

Sent the same compound from BCH and QST to PeptideMeter in the same month. Both came back above the claim on the certificate — mine was 99.6% on a stated 99.0%.

Limitless Life shows up in threads constantly and has almost nothing on file

What does the tolerability table say at that dose?

Which lane, and what was the quoted lead time at checkout?

the trials that looked at withdrawal are unambiguous about what follows

Agree. The verification log is the part with the checkable facts in it; the number at the top is just a summary of a lot of averaging.

What this compound is actually being developed for, since the boards treat it as a weight-loss molecule with a footnote.

It is a dual GLP-1 and glucagon receptor agonist, and the glucagon arm links to hepatic fat and energy expenditure. The headline programme is metabolic liver disease, with endpoints scored on biopsy rather than on a scale.

That matters for how the data should be read. A histological response rate in a biopsy-confirmed population answers a very different question from a mean weight change in an obesity trial, and quoting one in place of the other — which happens in nearly every thread here — is not a comparison.

Nothing here is medical or legal advice. The pharmacist and the prescriber are the people who can act, and both are faster than a forum.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

On stopping, since it is the question underneath most posts here.

Withdrawal studies in this class show substantial regain after discontinuation, consistently, across compounds. Appetite returns first, typically well before the scale moves. That is a statement about the pharmacology of a chronic condition, not about anybody’s character, and the framing matters because people quit in shame over an entirely predictable result.

If you are going to stop — for cost, for supply, for any reason — the useful preparation is deciding in advance what you will watch for and what your plan is when appetite comes back. Doing that in advance is much easier than doing it in a panic, and it is a conversation to have with someone who knows your history.

This. Correcting a wrong accusation in public is the hardest and most valuable post anybody makes here.

Not convinced.

This reframing is the most useful thing on the board for anyone approaching this phase.

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

That figure is from the obesity programme, and this thread is about the hepatic one.

Yes — interval stretching and dose reduction are different levers and people use the words interchangeably.

a claim with no batch number is a marketing document

Push back: approval by the national regulator says nothing about whether any plan will pay.

On stopping, since it is the question underneath most posts here.

Withdrawal studies in this class show substantial regain after discontinuation, consistently, across compounds. Appetite returns first, typically well before the scale moves. That is a statement about the pharmacology of a chronic condition, not about anybody’s character, and the framing matters because people quit in shame over an entirely predictable result.

If you are going to stop — for cost, for supply, for any reason — the useful preparation is deciding in advance what you will watch for and what your plan is when appetite comes back. Doing that in advance is much easier than doing it in a panic, and it is a conversation to have with someone who knows your history.

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table.